EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal …
EC Smyth, G Vlachogiannis, S Hedayat, A Harbery… - Gut, 2021 - gut.bmj.com
Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-
selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients …
selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients …
Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies,
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a …
T Waddell, I Chau, D Cunningham, D Gonzalez… - The lancet …, 2013 - thelancet.com
Background EGFR overexpression occurs in 27–55% of oesophagogastric
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …
Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III …
RD Petty, A Dahle-Smith, Z Miedzybrodzka, SJ Dutton… - 2014 - ascopubs.org
4016 Background: The Cancer Oesophagus Gefitinib (COG) trial randomised (1: 1) 450
patients (pts) with advanced EC who had progressed after 1-2 lines of chemotherapy to …
patients (pts) with advanced EC who had progressed after 1-2 lines of chemotherapy to …
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
TS Waddell, I Chau, Y Barbachano… - 2012 - ascopubs.org
LBA4000 Background: EGFR overexpression occurs in 27-50% of esophagogastric
adenocarcinomas (OGA), and correlates with poor prognosis. The REAL3 trial evaluated the …
adenocarcinomas (OGA), and correlates with poor prognosis. The REAL3 trial evaluated the …
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma
(GEA) were resoundingly negative. We identified EGFR amplification in 5%(19/363) of …
(GEA) were resoundingly negative. We identified EGFR amplification in 5%(19/363) of …
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced …
L Zhang, O Hamdani, O Gjoerup, C Cho-Phan… - JCO Precision …, 2022 - ascopubs.org
PURPOSE Human epidermal growth factor receptor 2 (HER2) overexpression or
amplification (ERBB2 amp) are biomarkers for approved anti-HER2 therapies. ERBB2 amp …
amplification (ERBB2 amp) are biomarkers for approved anti-HER2 therapies. ERBB2 amp …
Epidermal growth factor receptor inhibition in epidermal growth factor receptor–amplified gastroesophageal cancer: retrospective global experience
PURPOSE Subset analyses from phase III evaluation of epidermal growth factor receptor
inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified …
inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified …
Targeting EGFR in esophagogastric cancer
Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall
survival in the metastatic setting remains poor, with few molecular targeted approaches …
survival in the metastatic setting remains poor, with few molecular targeted approaches …
[HTML][HTML] FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma …
D Malka, E François, F Penault-Llorca, F Castan… - European Journal of …, 2019 - Elsevier
Background Epidermal growth factor receptor (EGFR) and hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition (MET) pathways, which promote tumour growth …
(HGF)/mesenchymal–epithelial transition (MET) pathways, which promote tumour growth …